Publications by authors named "S Manfredi"

Claim this Profile
E
Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer: the PRODIGE-13 FFCD phase III trial.
C Lepage, J-M Phelip, L Cany, E Barbier, S Manfredi

Ann Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 - FFCD-GONO - ENGIC 02 - FOLFIRINOX SBA phase II randomized trial.
Thomas Aparicio, Anthony Turpin, Aziz Zaanan, Christelle de la Fouchardière, Karine Le Malicot, Sylvain Manfredi

Dig Liver Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes of Atezolizumab-Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort.
Manon Allaire, Elhadji Malick Thiam, Guiliana Amaddeo, Mohamed Bouattour, Julien Edeline, Sylvain Manfredi

Liver Int· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life data on hepatocellular carcinoma in the French prospective CHIEF cohort in the era of immunotherapy.
Eric Nguyen-Khac, Philippe Merle, Hajer Ben Khadhra, Amaddeo Giuliana, Thomas Decaens, Sylvain Manfredi

Eur J Gastroenterol Hepatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial.
Aziz Zaanan, Olivier Bouché, Christelle de la Fouchardière, Karine Le Malicot, Simon Pernot, Sylvain Manfredi

Lancet Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis